Review
Oncology
Yvette N. Lamb
Summary: Osimertinib is an effective treatment for non-small cell lung cancer, prolonging survival and showing good tolerability in patients.
Article
Oncology
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Summary: A novel nomogram was created in this study to help physicians suggest the optimal treatment for EGFRm+ NSCLC patients. The nomogram was based on pretreatment factors and stratified patients into five different risk groups for progression-free survival (PFS) and overall survival (OS). This risk stratification can provide additional information for clinicians and patients in determining the optimal therapeutic options.
Article
Multidisciplinary Sciences
Qian Jin, Feihua Huang, Xianrong Xu, Haidong He, Yingqing Zhang
Summary: The study found that the expression of HIF-1 alpha in EGFR-TKIs sensitive NSCLC tissue was significantly higher, and the level of HIF-1 alpha increased further after acquiring resistance. There was a negative correlation between HIF-1 alpha level and the occurrence time of acquired resistance as well as the acquired EGFR T790M mutation.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Soon Hin How, Chong Kin Liam, Muhammad Adil Zainal Abidin, Harissa H. Hasbullah, Lye Mun Tho, Gwo Fuang Ho, Ibtisam Muhamad Nor, Yong Kek Pang, Kean Fatt Ho, Muthukkumaran Thiagarajan, Roziana Ariffin, Azlina Samsudin, Azza Omar, Sin Nee Tan, Choo Khoon Ong, Sing Yang Soon, Mau Ern Poh
Summary: This study describes the management and outcomes of EGFRm+ advanced NSCLC patients in an Asian cost-restrictive setting. The results suggest that the choice of first-line therapy, time on each line of treatment, and subsequent treatment options may adversely affect the overall survival of patients.
CANCER MANAGEMENT AND RESEARCH
(2022)
Article
Oncology
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Summary: In this multicenter clinical trial in China, we investigated the efficacy of adding pemetrexed to improve progression-free survival (PFS) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients. There were no significant differences in PFS between patients with or without concomitant alterations, or between patients receiving EGFR-tyrosine kinase inhibitor (TKI) monotherapy or combined with pemetrexed. However, stratification analysis revealed that TKI monotherapy showed better PFS in non-concomitant group, while TKI combined with pemetrexed showed better PFS in concomitant group. Molecular dynamic analysis supported the better efficacy of TKI combined chemotherapy compared to TKI monotherapy. Additionally, circulating tumor DNA (ctDNA) minimal residual disease (MRD) showed potential as a biomarker for predicting therapeutic efficacy.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Li Sun, Yi-Jia Guo, Jun Song, Yan-Ru Wang, Shu-Ling Zhang, Le-Tian Huang, Jian-Zhu Zhao, Wei Jing, Cheng-Bo Han, Jie-Tao Ma
Summary: The neoadjuvant EGFR-TKI therapy shows feasibility in treating patients with resectable or potentially resectable EGFR-mutant NSCLC, with satisfactory surgical outcomes and low toxicity. Further phase III clinical trials are needed to confirm these findings and explore the feasibility of a more effective EGFR-TKI combination neoadjuvant therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Hongxue Meng, Lan Huang, Jiahui Wang, Yingxu Zhou, Meng Wang, Zhaoyang Yang, Xuan Hong
Summary: A retrospective analysis of 67 patients with EGFR mutations who were switched to osimertinib after receiving first-generation EGFR-TKIs revealed that female patients and those who experienced isolated progression during first-line treatment may exhibit a better response to osimertinib. Additionally, a low frequency of the EGFR T790M allele in plasma samples may predict poor efficacy of osimertinib and shorter progression-free survival (PFS).
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
(2021)
Article
Oncology
Giorgia Nardo, Jessica Carlet, Ludovica Marra, Laura Bonanno, Alice Boscolo, Alessandro Dal Maso, Andrea Boscolo Bragadin, Stefano Indraccolo, Elisabetta Zulato
Summary: The study found that co-existing KRAS mutations in EGFR mutated NSCLC patients at progression after first-line EGFR TKI treatment are rare, and they have a negative impact on the response to EGFR TKI.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Hui Hua, Jiajia Zeng, Haixin Xing, Yuxin He, Linyu Han, Nasha Zhang, Ming Yang
Summary: This study systematically evaluated the role of genetic variants in A-to-I editing genes on the prognosis of NSCLC patients receiving EGFR-TKIs therapy. The researchers identified several SNPs in the ADAR gene that were significantly associated with patient prognosis and found that silencing ADAR enhanced the sensitivity of NSCLC cells to gefitinib. These findings highlight the importance of A-to-I RNA editing in drug resistance and suggest ADAR as a potential therapeutic target for unresectable NSCLC.
Review
Oncology
Michela Verze, Roberta Minari, Letizia Gnetti, Paola Bordi, Alessandro Leonetti, Agnese Cosenza, Leonarda Ferri, Maria Majori, Massimo De Filippo, Sebastiano Buti, Donatello Gasparro, Rita Nizzoli, Cinzia Azzoni, Lorena Bottarelli, Anna Squadrilli, Paola Mozzoni, Marcello Tiseo
Summary: The study aimed to explore the potential of liquid biopsy in advanced EGFR mutated NSCLC patients, with results confirming the importance of plasma in detecting EGFR mutation status but showing no significant improvement from alternative sources such as urine and exhaled breath condensate.
Review
Oncology
Kunyu Shi, Guan Wang, Junping Pei, Jifa Zhang, Jiaxing Wang, Liang Ouyang, Yuxi Wang, Weimin Li
Summary: This review discusses the molecular mechanisms of resistance to third-generation EGFR inhibitors and reviews recent strategies for overcoming resistance, new challenges, and future development directions.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Oncology
Yihua Huang, Chunwei Xu, Yuanliang Sun, Wenxian Wang, Xingya Li, Jun Liao, Lanlan Pang, Liang Zeng, Juan Li, Xihua Wang, Qi Zhang, Zhanhong Xie, Lin Xiao, Jiadi Gan, Wenfeng Fang
Summary: This study investigated the molecular distribution and clinical outcomes of Chinese patients with EGFR E709-T710delinsX mutations. The results showed that afatinib may have superior antitumor activity compared to 1G EGFR TKIs and chemotherapy in EGFR E709-T710delinsX mutant patients.
Article
Biochemistry & Molecular Biology
Hong-Yi Zhao, Xiao-Xiao Xi, Minhang Xin, San-Qi Zhang
Summary: The third-generation EGFR-TKIs have shown significant clinical achievements in NSCLC treatment, but acquired drug resistance remains a major limitation. The development of fourth-generation EGFR-TKIs targeting the triple mutant EGFR with C797S mutation has gained much attention. This review outlines the current panorama of fourth-generation EGFR-TKIs, focusing on their design strategy, binding mode, and antitumor activity. The challenges and prospects of fourth-generation EGFR-TKIs are also discussed.
BIOORGANIC CHEMISTRY
(2022)
Review
Pharmacology & Pharmacy
Yazan Haddad, Marek Remes, Vojtech Adam, Zbynek Heger
Summary: The study utilized variations in 110 crystal structures to assemble eight distinct families highlighting the C-helix orientation in the N-lobe of the EGFR kinase domain. These families shared similar mutational profiles, ligand R-groups facing the C-helix, mutation sites, and DFG domain.
DRUG DISCOVERY TODAY
(2021)
Article
Oncology
Michael Cekay, Philipp F. Arndt, Rio Dumitrascu, Rajkumar Savai, Andreas Braeuninger, Stefan Gattenloehner, Dagmar Steiner, Fritz Roller, Khodr Tello, Katja Hattar, Werner Seeger, Ulf Sibelius, Friedrich Grimminger, Bastian Eul
Summary: This study reports a case of a lung adenocarcinoma patient with EGFR mutation who showed significant therapeutic response to Osimertinib, which is the first report of effective treatment of this specific mutation with Osimertinib. Therefore, Osimertinib may be a viable treatment option for EGFR Exon 18 p.Glu709_Thr710delinsAsp mutated lung adenocarcinoma.
FRONTIERS IN ONCOLOGY
(2023)
